GBGaetano Bacci

Gaetano Bacci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gaetano Bacci has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Local and systemic control of Ewing's bone sarcoma family tumors of the ribs

    by Antonio Briccoli, Michele Rocca, Mariacristina Salone, Emanuela Palmerini, Alba Balladelli Ba, Cristina Ferrari, Maria Di Fiore, Gaetano Bacci

    Background: A retrospective analysis of the results and relapse pattern was evaluated in 34 patients with Ewing's family bone tumors (EFBT) treated at Rizzoli Institute with neoadjuvant chemotherapy between 1983 and 2003.Objectives: The aim of the study was to evaluate treatment strategy and compare our results with those obtained in other studies.Methods: Local treatment in these patients was radiotherapy alone in 4 cases, surgery alone in 13 and surgery followed by radiotherapy in 17.Results: Five‐year event‐free survival (EFS) was 44%, no different from that observed in another 558 patients with EFBT located in other sites treated in the same period with neoadjuvant chemotherapy protocols. Eighteen patients had a systemic relapse, followed by local relapse in two and one patient had a local relapse alone. EFS was significantly correlated to the time interval between onset symptoms and beginning of treatment and, in operated patients to histologic response to preoperative treatment.Conclusions: We conclude that EFBT of the ribs, when treated with neoadjuvant chemotherapy, have an outcome similar to that of patients with EFBT located in other sites. J. Surg. Oncol. 2009;100:222–226.


  • Diagnosis and prognosis for the Ewing family of tumors

    by Emanuela Palmerini, Eric L Staals, Stefano Ferrari, Gaetano Bacci, Md

    (2009). Diagnosis and prognosis for the Ewing family of tumors. Expert Opinion on Medical Diagnostics: Vol. 3, No. 4, pp. 445-452. doi: 10.1517/17530050902832830


  • Treatment of nonmetastatic Ewing’s sarcoma family tumors of the spine and sacrum: the experience from a single institution

    by Gaetano Bacci, Stefano Boriani, Alba Balladelli, Enza Barbieri, Alessandra Longhi, Marco Alberghini, Katia Scotlandi, Cristiana Forni, Paola Pollastri, Daniel Vanel, et al.

    The objective of this study is to determine the best local treatment combined with neoadjuvant chemotherapy for ESFT of the spine and sacrum, for the best local treatment for Ewing sarcoma family tumors (ESFT) according to the primary site is still unclear. Nowadays surgery is used in local treatment of ESFT, but literature is scarce on the best local treatment in sites where surgery is problematic, such as the spine. This study evaluates the outcome and the rate of local recurrence of ESFT in the spine and sacrum when treated with neoadjuvant chemotherapy, and locally by radiotherapy alone or surgery, followed by reduced doses of radiotherapy. Forty-three patients with nonmetastatic ESFT located in the spine and sacrum were treated at our institution between 1983 and 2000 with neoadjuvant chemotherapy, and locally by radiotherapy alone in 26 cases, and surgery followed by radiotherapy at reduced doses in 17. The 5- and 10-year event-free survival (EFS) was 37 and 30%, and the 5- and 10-year overall survival was (OS) 42 and 32%. The prognosis was unrelated to gender and age, tumor volume, chemotherapy protocol, and local treatment. The outcome seemed worse for patients with primary tumors located in the sacrum than for patients with tumors located in the rest of the spine (5-year EFS = 23 vs. 46%). For these patients the results were significantly worse than for those we achieved with neoadjuvant treatment for ESFT located in other sites. However, no differences were observed between patients locally treated with radiotherapy alone and those treated by radiotherapy followed by surgery. We concluded that regardless of the type of local treatment even when associated with neoadjuvant therapy, ESFT in the spine and sacrum has a poor outcome and prognosis is significantly worse than that of primary ESFT in other sites.


  • Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent Patients

    by Gaetano Bacci, Alba Balladelli, Emanuela Palmerini, Marco Alberghini, Paola Pollastri, Stefano Galletti, Mario Mercuri, Piero Picci

    Medical records of 133 patients, 10 years old or younger with primary high-grade nonmetastatic osteosarcoma of the extremities treated at the Rizzoli Institute between 1983 and 1999 with neoadjuvant chemotherapy were reviewed and compared with those of 782 patients aged 11 to 40 years treated in the same period with the same chemotherapy protocols. In comparison to the older group, the younger group had more females, more patients with normal lactic dehydrogenase levels, and more non-limb-salvage procedures (amputation or rotationplasty). Five-year event-free and overall survivals were essentially the same in the two groups (63% and 71% vs. 60% and 70%) as were the patients rescued after relapse and presently event-free (18% vs. 20%). The authors conclude that there does not seem to be any indication to treat preadolescent primary high-grade nonmetastatic osteosarcoma patients by alternative and/or more aggressive therapies.


  • High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions

    by Gaetano Bacci, Michele Rocca, MariaCristina Salone, Alba Balladelli Ba, Stefano Ferrari, Emanuela Palmerini, Cristiana Forni, Antonio Briccoli

    Background and Methods: Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy.Results: After neoadjuvant chemotherapy, metastases disappeared in 14 patients, 16 were judged unresectable by both our thoracic surgeons, 132 had primary tumors and lung metastases removed simultaneously. Removal of lung metastases was complete in 123 and incomplete in 9. Histologically lesions were benign in 32 patients. For the 100 patients simultaneously operated with histologically proven lung metastases, 5‐year event‐free survival (EFS) was 18.9%; 27.4% for the 91 who had a complete resection of pulmonary lesions and entered remission as opposed to none for 9 patients who had incomplete removal of lung nodules. Among these 91, 5‐year EFS was significantly higher for patients with monolateral compared to bilateral lesions (27.1% vs. 7.9%, P < 0.02) and when only one to three metastatic nodules were present (40.0% vs. 13.3%, P < 0.0001).Conclusions: These different results, demonstrate that our treatment had a reasonable survival outcome whereas other groups continue to have dismal prognosis. More efforts should be made to improve survival by identifying new active agents or novel approaches with cellular molecular targets. J. Surg. Oncol.


  • Spontaneous Regression of Lung Metastasis From Osteosarcoma: A Case Report

    by Gaetano Bacci, Emanuela Palmerini, Eric L. Staals, Stefano Ferrari, Milva Battaglia, Alessandra Longhi, Franco Bertoni, Antonio Briccoli

    A case of spontaneous regression of a pulmonary metastasis from high-grade osteosarcoma is reported. The metastasis developed 5 years after chemotherapy and amputation for a distal femur osteosarcoma. The sarcomatous nature of the lesion was histologically confirmed. No treatment was attempted owing to the patient's refusal. The patient was followed up every 3 months and a spontaneous regression of the lesion was documented. Seven years after the diagnosis of lung metastases, no pulmonary nodules or other signs of relapse are present.


  • Open Access

    Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment

    by G. Bacci, A. Balladelli, C. Forni, S. Ferrari, A. Longhi, M. S. Benassi, A. Briccoli, M. Serra, P. Picci

    Background: In 326 patients with Ewing's sarcoma family tumor (ESFT) and 628 extremity osteosarcoma (OS) treated with adjuvant and neo-adjuvant chemotherapy and event-free survivors 5 years from the beginning of treatment we evaluated outcome in the following years. Post 5-year follow-up for these patients was 9.7 years (5.5–29 years). Patients and methods: Adverse events observed after 5-year follow-up were 73 (7.6%): 38 late relapses, nine leukemia, 14 second solid tumor, seven radioinduced sarcoma, three severe adriamycin-related cardiomyopathy, one suicide and one death by car crash. Results: Of the patients who developed late events, 16 (22.5%) are alive and event free after 8 years from the last treatment (2–22 years). Conclusion: We conclude that the high rate of late adverse events after 5 years in patients with OS and ESFT is noteworthy and indicates that these patients should be followed for >5 years.


  • Ewing’s sarcoma family tumours

    by G. Bacci, A. Balladelli, C. Forni, A. Longhi, M. Serra, N. Fabbri, M. Alberghini, S. Ferrari, M. S. Benassi, P. Picci

    Despite local treatment with systemic chemotherapy in Ewing’s sarcoma family tumours (ESFT), patients with detectable metastases at presentation have a markedly worse prognosis than those with apparently localised disease. We investigated the clinical, pathological and laboratory differences in 888 patients with ESFT, 702 with localised disease and 186 with overt metastases at presentation, seen at our institution between 1983 and 2006. Multivariate analyses showed that location in the pelvis, a high level of serum lactic dehydrogenase, the presence of fever and a short interval between the onset of symptoms and diagnosis were indicative of metastatic disease. The rate of overt metastases at presentation was 10% without these four risk factors, 22.7% with one, 31.4% with two, and 50% for those with three or four factors. We concluded that in ESFT the site, the serum level of lactic dehydrogenase, fever, and the interval between the onset of symptoms and diagnosis are indicators of tumours having a particularly aggressive metastatic behaviour.


  • Local recurrence and local control of non‐metastatic osteosarcoma of the extremities: A 27‐year experience in a single institution

    by Gaetano Bacci, Cristiana Forni, Alessandra Longhi, Stefano Ferrari, Mario Mercuri, Franco Bertoni, Massimo Serra, Antonio Briccoli, Alba Balladelli Ba, Piero Picci

    Background: Indications and contraindications for limb salvage versus amputation for local treatment of osteosarcoma of the extremity are still controversial.Patients and Methods: Patients (1,126) with non‐metastatic osteosarcoma of the extremity, treated in a single institution between 1972 and 1999 with different protocols of adjuvant and neoadjuvant chemotherapy were evaluated to establish factors that could influence local recurrence (LR) and outcome.Results: The 5‐year event‐free survival and overall survival were 55% and 66%. At a follow‐up ranging between 5.5 and 32.5 years (mean18.6 years) of the 1,126 evaluated patients, 607 (54%) remained continuously disease‐free and 519 relapsed. LR developed in 61 patients (5.4%) after a median time of 2.3 years (0.2–17). For this group of patients the 5‐year post‐relapse event‐free survival and overall survival from the last relapse were, respectively, 11.4% and 16.4%. At the multivariate analyses only surgical margins and histologic response to preoperative treatment resulted to be independent prognostic factors for LR.Conclusion: Considering the risk of LR after surgery with inadequate surgical margins and poor prognosis of LR in osteosarcoma, limb salvage procedures should be performed only when adequate margins surgical margins can be achieved. In case of inadequate margins, an immediate amputation should be considered. J. Surg. Oncol. 2007;96:118–123.